Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Cardiff Oncology (CRDF) over the last 15 years, with Q2 2025 value amounting to -$1000.0.

  • Cardiff Oncology's Other Non Operating Income rose 9736.84% to -$1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year increase of 10800.0%. This contributed to the annual value of -$39000.0 for FY2024, which is 6020.41% up from last year.
  • Per Cardiff Oncology's latest filing, its Other Non Operating Income stood at -$1000.0 for Q2 2025, which was up 9736.84% from $7000.0 recorded in Q1 2025.
  • Cardiff Oncology's 5-year Other Non Operating Income high stood at $207000.0 for Q1 2021, and its period low was -$253000.0 during Q2 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was -$1500.0 (2024), whereas its average is -$12722.2.
  • Per our database at Business Quant, Cardiff Oncology's Other Non Operating Income surged by 700000.0% in 2021 and then plummeted by 100000.0% in 2022.
  • Cardiff Oncology's Other Non Operating Income (Quarter) stood at $5000.0 in 2021, then plummeted by 1000.0% to -$45000.0 in 2022, then skyrocketed by 71.11% to -$13000.0 in 2023, then soared by 84.62% to -$2000.0 in 2024, then skyrocketed by 50.0% to -$1000.0 in 2025.
  • Its Other Non Operating Income was -$1000.0 in Q2 2025, compared to $7000.0 in Q1 2025 and -$2000.0 in Q4 2024.